Shield Therapeutics Past Earnings Performance
Past criteria checks 0/6
Shield Therapeutics's earnings have been declining at an average annual rate of -51.5%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually. Revenues have been declining at an average rate of 13.5% per year.
Key information
-51.5%
Earnings growth rate
-30.4%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | -13.5% |
Return on equity | -221.5% |
Net Margin | -254.4% |
Next Earnings Update | 04 Sep 2024 |
Recent past performance updates
Recent updates
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Revenue & Expenses Breakdown
How Shield Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 13 | -33 | 38 | 2 |
30 Sep 23 | 10 | -40 | 37 | 1 |
30 Jun 23 | 7 | -49 | 37 | 0 |
31 Mar 23 | 6 | -49 | 35 | 1 |
31 Dec 22 | 5 | -50 | 34 | 1 |
30 Sep 22 | 5 | -39 | 32 | 1 |
30 Jun 22 | 4 | -30 | 32 | 0 |
31 Mar 22 | 3 | -29 | 30 | 1 |
31 Dec 21 | 2 | -27 | 27 | 1 |
30 Sep 21 | 2 | -22 | 20 | 3 |
30 Jun 21 | 3 | -18 | 14 | 5 |
31 Mar 21 | 9 | -11 | 13 | 4 |
31 Dec 20 | 14 | -4 | 12 | 4 |
30 Sep 20 | 13 | -3 | 11 | 3 |
30 Jun 20 | 11 | -2 | 10 | 2 |
31 Mar 20 | 6 | -6 | 9 | 3 |
31 Dec 19 | 1 | -12 | 9 | 3 |
30 Sep 19 | 8 | -4 | 10 | 4 |
30 Jun 19 | 15 | 3 | 12 | 4 |
31 Mar 19 | 15 | 0 | 14 | 5 |
31 Dec 18 | 15 | -2 | 16 | 5 |
30 Sep 18 | 8 | -13 | 18 | 6 |
30 Jun 18 | 1 | -24 | 20 | 6 |
31 Mar 18 | 1 | -26 | 22 | 7 |
31 Dec 17 | 1 | -26 | 23 | 6 |
30 Sep 17 | 1 | -24 | 20 | 5 |
30 Jun 17 | 0 | -21 | 18 | 4 |
31 Mar 17 | 0 | -19 | 15 | 3 |
31 Dec 16 | 0 | -19 | 13 | 3 |
30 Sep 16 | 0 | -12 | 11 | 4 |
30 Jun 16 | 0 | -4 | 8 | 6 |
31 Mar 16 | 0 | -19 | 5 | 7 |
31 Dec 15 | 0 | -35 | 2 | 8 |
30 Sep 15 | 0 | -41 | 2 | 6 |
30 Jun 15 | 0 | -49 | 2 | 4 |
31 Mar 15 | 0 | -33 | 2 | 4 |
31 Dec 14 | 0 | -20 | 2 | 4 |
31 Dec 13 | 0 | -7 | 2 | 5 |
Quality Earnings: STX is currently unprofitable.
Growing Profit Margin: STX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STX is unprofitable, and losses have increased over the past 5 years at a rate of 51.5% per year.
Accelerating Growth: Unable to compare STX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).
Return on Equity
High ROE: STX has a negative Return on Equity (-221.47%), as it is currently unprofitable.